TNF receptor 2 pathway: drug target for autoimmune diseases
暂无分享,去创建一个
[1] D. Harlan,et al. A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes , 2005, Diabetes.
[2] E. Unanue,et al. Immunological Reversal of Autoimmune Diabetes Without Hematopoietic Replacement of ß Cells , 2006, Science.
[3] B. Millward,et al. NFκB Polymorphisms and susceptibility to type 1 diabetes , 2001, Genes and Immunity.
[4] R N Maini,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.
[5] Y. Yoshioka,et al. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. , 2009, Journal of molecular biology.
[6] A. Cope,et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. , 1992, Arthritis and rheumatism.
[7] P. Emery,et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. , 2003, The Journal of rheumatology.
[8] R. Beyaert,et al. Function and regulation of tumor necrosis factor receptor type 2. , 2004, Current medicinal chemistry.
[9] N. Maclaren,et al. Association of LMP2 and LMP7 genes within the major histocompatibility complex with insulin-dependent diabetes mellitus: population and family studies. , 1995, American journal of human genetics.
[10] D. Goeddel,et al. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75 , 1995, The Journal of experimental medicine.
[11] Takuma Hayashi,et al. Reply to 'LMP2 expression and proteasome activity in NOD mice' , 2000, Nature Medicine.
[12] R. Brink,et al. Tumor Necrosis Factor Receptor 2 (TNFR2) Signaling Is Negatively Regulated by a Novel, Carboxyl-terminal TNFR-associated Factor 2 (TRAF2)-binding Site* , 2005, Journal of Biological Chemistry.
[13] Tumor necrosis factor-α is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction , 2007 .
[14] A. Kuznetsov,et al. Reversal of Diabetes in Non-Obese Diabetic Mice Without Spleen Cell-Derived ß Cell Regeneration , 2006, Science.
[15] É. Mezey,et al. Reversal of Sjögren’s-like syndrome in non-obese diabetic mice , 2006, Annals of the rheumatic diseases.
[16] U. Hieber,et al. Tumor necrosis factor for the treatment of malignancies. , 1994, Oncology.
[17] Y. Fu,et al. Abnormal class I assembly and peptide presentation in the nonobese diabetic mouse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[18] G. Kollias,et al. Tumor necrosis factor‐receptor 2 is up‐regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo , 2002, European journal of immunology.
[19] Javier Martín,et al. Study of functional variants of the BANK1 gene in rheumatoid arthritis. , 2009, Arthritis and rheumatism.
[20] R. Flavell,et al. A Dual Role for TNF-α in Type 1 Diabetes: Islet-Specific Expression Abrogates the Ongoing Autoimmune Process When Induced Late but Not Early During Pathogenesis1 , 2001, The Journal of Immunology.
[21] P. V. van Riel,et al. Development of type 1 diabetes in a patient treated with anti-TNF-α therapy for active rheumatoid arthritis , 2009, Diabetologia.
[22] K. Schlett,et al. Tumor Necrosis Factor (TNF)-mediated Neuroprotection against Glutamate-induced Excitotoxicity Is Enhanced by N-Methyl-D-aspartate Receptor Activation , 2004, Journal of Biological Chemistry.
[23] A. Silman,et al. Association between rheumatoid arthritis and polymorphism of tumor necrosis factor receptor II, but not tumor necrosis factor receptor I, in Caucasians. , 2001, Arthritis and rheumatism.
[24] S. Pervaiz,et al. TNF receptor superfamily‐induced cell death: redox‐dependent execution , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[25] S. Mohand-Said,et al. Neurodegenerative and Neuroprotective Effects of Tumor Necrosis Factor (TNF) in Retinal Ischemia: Opposite Roles of TNF Receptor 1 and TNF Receptor 2 , 2002, The Journal of Neuroscience.
[26] M. Kubeš,et al. TNF signaling: early events and phosphorylation. , 2007, General physiology and biophysics.
[27] L. Kuller,et al. The Pittsburgh Insulin-dependent Diabetes Mellitus (IDDM) Morbidity and Mortality Study: Mortality Results , 1984, Diabetes.
[28] V. Werth,et al. Leukocytoclastic vasculitis due to etanercept. , 2000, The Journal of rheumatology.
[29] Li-BoChen,et al. Differentiation of rat marrow mesenchymal stem cells into pancreatic islet beta-cells , 2004 .
[30] T. Vischer,et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. , 1997, The Journal of rheumatology.
[31] D. Furst,et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. , 1999, Annals of internal medicine.
[32] C. Ware,et al. Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells. , 1991, Journal of immunology.
[33] D. Furst,et al. Etanercept Therapy in Rheumatoid Arthritis , 1999, Annals of Internal Medicine.
[34] D. Faustman,et al. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism , 2008, Proceedings of the National Academy of Sciences.
[35] D. Banner,et al. Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. , 1993, The Journal of biological chemistry.
[36] R. Gentz,et al. Both tumor necrosis factor receptor types mediate proliferative signals in human mononuclear cell activation. , 1992, Journal of immunology.
[37] M. Matsumoto,et al. Analysis of the roles of CD4+ and CD8+ T cells in autoimmune diabetes of NOD mice using transfer to NOD athymic nude mice , 1992, European journal of immunology.
[38] P. Rosenstiel,et al. The Met-196 → Arg Variation of Human Tumor Necrosis Factor Receptor 2 (TNFR2) Affects TNF-α-induced Apoptosis by Impaired NF-κB Signaling and Target Gene Expression* , 2005, Journal of Biological Chemistry.
[39] Takuma Hayashi,et al. Essential Role of Human Leukocyte Antigen-encoded Proteasome Subunits in NF-κB Activation and Prevention of Tumor Necrosis Factor-α-induced Apoptosis* , 2000, The Journal of Biological Chemistry.
[40] E. Leiter,et al. Adoptive Transfer of Diabetes Into Immunodeficient NOD-scid/scid Mice: Relative Contributions of CD4+ and CD8+ T-Cells From Diabetic Versus Prediabetic NOD.NON-Thy-1a Donors , 1993, Diabetes.
[41] J. Tschopp,et al. Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes , 2003, Cell.
[42] M. Croft. The role of TNF superfamily members in T-cell function and diseases , 2009, Nature Reviews Immunology.
[43] P. V. van Riel,et al. Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study , 2005, Arthritis research & therapy.
[44] P. Scheurich,et al. Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: requirement of the TNF receptor-associated factor-2 binding site. , 1997, Journal of immunology.
[45] M. Feldmann,et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. , 2000, Arthritis and rheumatism.
[46] D. Goeddel,et al. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40 , 1995, Science.
[47] J. Drijfhout,et al. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[48] D. Wagener,et al. The Pittsburgh Insulin-dependent Diabetes Mellitus (IDDM) Morbidity and Mortality Study: Case-Control Analyses of Risk Factors for Mortality , 1985, Diabetes Care.
[49] D. Schoenfeld,et al. Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. , 2001, The Journal of clinical investigation.
[50] B. Aggarwal. Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.
[51] K Suzuki,et al. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. , 2001, Nature neuroscience.
[52] M. Tansey,et al. Journal of Neuroinflammation BioMed Central Review , 2008 .
[53] P. Secchiero,et al. Tumour necrosis factor‐related apoptosis‐inducing ligand sequentially activates pro‐survival and pro‐apoptotic pathways in SK‐N‐MC neuronal cells , 2003, Journal of neurochemistry.
[54] D. Mann,et al. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. , 1999, Circulation.
[55] M. Sadelain,et al. Prevention of diabetes in the BB rat by early immunotherapy using Freund's adjuvant. , 1990, Journal of autoimmunity.
[56] Takuma Hayashi,et al. NOD Mice Are Defective in Proteasome Production and Activation of NF-κB , 1999, Molecular and Cellular Biology.
[57] J. Stockman. Insulin Needs After CD3-Antibody Therapy in New-Onset Type 1 Diabetes , 2007 .
[58] G. Galbraith,et al. TRAF1-C5 as a Risk Locus for Rheumatoid Arthritis—A Genomewide Study , 2008 .
[59] M. Dorf,et al. PKC phosphorylation of TRAF2 mediates IKKalpha/beta recruitment and K63-linked polyubiquitination. , 2009, Molecular cell.
[60] M. Karin,et al. NOD2 and Crohn's disease: loss or gain of function? , 2005, Immunity.
[61] D. Huscher,et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonists , 2005, Annals of the rheumatic diseases.
[62] Judy H. Cho,et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. , 2004, Human molecular genetics.
[63] P. Scheurich,et al. Tumor necrosis factor (TNF) receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1 , 1998, European journal of immunology.
[64] D. Faustman,et al. Islet Regeneration During the Reversal of Autoimmune Diabetes in NOD Mice , 2003, Science.
[65] Bhagirath Singh,et al. In vivo apoptosis of diabetogenic T cells in NOD mice by IFN-γ/TNF-α , 2004 .
[66] P. Kloetzel,et al. Immunoproteasome subunit LMP2 expression is deregulated in Sjögren’s syndrome but not in other autoimmune disorders , 2006, Annals of the rheumatic diseases.
[67] Y. Fu,et al. Reduced expression of Tap1 and Lmp2 antigen-processing genes in the nonobese diabetic (NOD) mouse due to a mutation in their shared bidirectional promoter. , 1997, Journal of immunology.
[68] H. Ding,et al. Relationship of large multifunctional proteasome 7 gene polymorphism with susceptibility to type 1 diabetes mellitus and DR3 gene. , 2001, Chinese medical journal.
[69] Rena Li,et al. Inhibition of p75 Tumor Necrosis Factor Receptor by Antisense Oligonucleotides Increases Hypoxic Injury and β-Amyloid Toxicity in Human Neuronal Cell Line* , 1997, The Journal of Biological Chemistry.
[70] F. Breedveld,et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.
[71] W. Hagopian,et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. , 2009, Clinical immunology.
[72] E. Fonseca,et al. Psoriasiform Eruption Induced by Infliximab , 2004, The Annals of pharmacotherapy.
[73] M. Lenardo. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. , 1991, Nature.
[74] G. Tsokos,et al. Abnormal T lymphocyte signal transduction in systemic lupus erythematosus. , 2002, Current directions in autoimmunity.
[75] B. Seed,et al. Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. , 1999, Immunity.
[76] N. Taylor,et al. Tumor Necrosis Factor Promotes Human T‐Cell Development in Nonobese Diabetic/Severe Combined Immunodeficient Mice , 2004, Stem Cells.
[77] H. Inoko,et al. Polymorphisms in TNFA and TNFR2 affect outcome of unrelated bone marrow transplantation , 2002, Bone Marrow Transplantation.
[78] D. Goeddel,et al. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor , 1994, Cell.
[79] Tomohiro Watanabe,et al. NOD2 is a negative regulator of Toll-like receptor 2–mediated T helper type 1 responses , 2004, Nature Immunology.
[80] Vishva Dixit,et al. Death receptor signal transducers: nodes of coordination in immune signaling networks , 2009, Nature Immunology.
[81] A. Hoffmann,et al. Circuitry of nuclear factor kappaB signaling. , 2006, Immunological reviews.
[82] J. Gaglia,et al. Islet Recovery and Reversal of Murine Type 1 Diabetes in the Absence of Any Infused Spleen Cell Contribution , 2006, Science.
[83] K. Kretschmer,et al. Making regulatory T cells with defined antigen specificity: role in autoimmunity and cancer , 2006, Immunological reviews.
[84] B. Prum,et al. Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: evidence for genetic heterogeneity. , 2002, Arthritis and rheumatism.
[85] K. Herold,et al. Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3gamma1 (Ala-Ala). , 2008, Human immunology.
[86] M. Feldmann,et al. Role of cytokines in rheumatoid arthritis. , 1996, Annual review of immunology.
[87] Y. Fu,et al. Linkage of faulty major histocompatibility complex class I to autoimmune diabetes. , 1991, Science.
[88] Dae Kim,et al. AIMP2 promotes TNFα-dependent apoptosis via ubiquitin-mediated degradation of TRAF2 , 2009, Journal of Cell Science.
[89] C. Janeway,et al. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library , 1999, Nature Medicine.
[90] I. Rosner,et al. Increased CD8+ T Cell Apoptosis in Scleroderma Is Associated with Low Levels of NF-κB , 2004, Journal of Clinical Immunology.
[91] S. Macura,et al. Tumor Necrosis Factor α is Reparative via TNFR1 in the Hippocampus and via TNFR2 in the Striatum after Virus‐Induced Encephalitis , 2009, Brain pathology.
[92] M. Slevin,et al. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. , 1990, Cytokine.
[93] C. Janeway,et al. Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells , 1996, The Journal of experimental medicine.
[94] K. Tokunaga,et al. Association of tumor necrosis factor receptor 2 (TNFR2) polymorphism with susceptibility to systemic lupus erythematosus. , 1999, Tissue antigens.
[95] U. Chaudhari,et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial , 2001, The Lancet.
[96] J. Killestein. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. , 2002, The New England journal of medicine.
[97] K. Van Steen,et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. , 2003, Gastroenterology.
[98] G. Kollias,et al. Tumor Necrosis Factor (TNF) Receptor Shedding Controls Thresholds of Innate Immune Activation That Balance Opposing TNF Functions in Infectious and Inflammatory Diseases , 2004, The Journal of experimental medicine.
[99] P. Scheurich,et al. TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60. , 1998, Journal of immunology.
[100] J. Satoh,et al. Recombinant human tumor necrosis factor alpha suppresses autoimmune diabetes in nonobese diabetic mice. , 1989, The Journal of clinical investigation.
[101] V. D’Agati,et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[102] George Kollias,et al. A Critical Role of the p75 Tumor Necrosis Factor Receptor (p75TNF-R) in Organ Inflammation Independent of TNF, Lymphotoxin α, or the p55TNF-R , 1998, The Journal of experimental medicine.
[103] D. Männel,et al. Cutting Edge: Expression of TNFR2 Defines a Maximally Suppressive Subset of Mouse CD4+CD25+FoxP3+ T Regulatory Cells: Applicability to Tumor-Infiltrating T Regulatory Cells1 , 2008, The Journal of Immunology.
[104] E. Leshinsky‐Silver,et al. TNF Promoter Polymorphisms and Modulation of Growth Retardation and Disease Severity in Pediatric Crohn's Disease , 2005, The American Journal of Gastroenterology.
[105] T. Hayashi,et al. Selected contribution: Association of gender-related LMP2 inactivation with autoimmune pathogenesis. , 2001, Journal of applied physiology.
[106] I. Georgiou,et al. The role of tumor necrosis factor (TNF)-alpha and TNF receptor polymorphisms in susceptibility to ankylosing spondylitis. , 2009, Clinical and experimental rheumatology.
[107] F. Balkwill. Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.
[108] M. Lenardo,et al. Requirement for TNF-alpha and IL-1 alpha in fetal thymocyte commitment and differentiation. , 1995, Science.
[109] L. Cantley,et al. The Crohn's Disease Protein, NOD2, Requires RIP2 in Order to Induce Ubiquitinylation of a Novel Site on NEMO , 2004, Current Biology.
[110] J. Vauthey,et al. A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon , 1996, The Journal of experimental medicine.
[111] R. Offringa,et al. C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L , 2005, Nature chemical biology.
[112] A. Klinkhoff. Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. , 2004, Drugs.
[113] K. Sunagawa,et al. Tumor necrosis factor-alpha is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction. , 2007, American journal of physiology. Heart and circulatory physiology.
[114] J. Tschopp,et al. The RIP kinases: crucial integrators of cellular stress. , 2005, Trends in biochemical sciences.
[115] R. Gentz,et al. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. , 1990, Cytokine.
[116] G. Tilz,et al. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis , 1995, European journal of haematology.
[117] Crystallization and preliminary X-ray analysis of the tumour necrosis factor alpha-tumour necrosis factor receptor type 2 complex. , 2009, Acta crystallographica. Section F, Structural biology and crystallization communications.
[118] Rena Li,et al. Target Depletion of Distinct Tumor Necrosis Factor Receptor Subtypes Reveals Hippocampal Neuron Death and Survival through Different Signal Transduction Pathways , 2002, The Journal of Neuroscience.
[119] S. Deventer,et al. Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-α antibody , 2005, Journal of Clinical Immunology.
[120] D. Faustman,et al. The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies , 2009, Journal of Molecular Medicine.
[121] Ingela Parmryd,et al. Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. , 2002, Journal of cell science.
[122] A. Bollon,et al. Tumor necrosis factor activities and cancer therapy--a perspective. , 1993, Pharmacology & therapeutics.
[123] F. Spinella,et al. Expression of the p75 TNF Receptor Is Linked to TNF-Induced NFκB Translocation and Oxyradical Neutralization in Glial Cells , 2002, Neurochemical Research.
[124] N. Amariglio,et al. TNF Activates a NF-κB–Regulated Cellular Program in Human CD45RA– Regulatory T Cells that Modulates Their Suppressive Function , 2010, The Journal of Immunology.
[125] Michael Karin,et al. Nod2 Mutation in Crohn's Disease Potentiates NF-κB Activity and IL-1ß Processing , 2005, Science.
[126] L. Tartaglia,et al. A novel domain within the 55 kd TNF receptor signals cell death , 1993, Cell.
[127] J. Drijfhout,et al. Autoreactive CD8 T cells associated with β cell destruction in type 1 diabetes , 2005 .
[128] S. Böhringer,et al. Inhibitors in the NFκB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations , 2002, Genes and Immunity.
[129] L. Cardon,et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors. , 2002 .
[130] Jun Wang,et al. Small-Molecule Inhibition of TNF-α , 2005, Science.
[131] Peter Scheurich,et al. Control of Receptor-induced Signaling Complex Formation by the Kinetics of Ligand/Receptor Interaction* , 2002, The Journal of Biological Chemistry.
[132] D. Docheva,et al. IKK-2 is required for TNF-α-induced invasion and proliferation of human mesenchymal stem cells , 2008, Journal of Molecular Medicine.
[133] Meijing Wang,et al. Mechanisms of Sex Differences in TNFR2-Mediated Cardioprotection , 2008, Circulation.
[134] W. Fiers,et al. Cytotoxicity in L929 murine fibrosarcoma cells after triggering of transfected human p75 tumour necrosis factor (TNF) receptor is mediated by endogenous murine TNF. , 1995, Cytokine.
[135] K. Tamura,et al. Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively , 2002, Immunogenetics.
[136] Yili Yang,et al. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2 , 2002, Nature.
[137] P. Rutgeerts,et al. Tumour necrosis factor‐α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab , 2004, Alimentary pharmacology & therapeutics.
[138] R L Kassel,et al. An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[139] D. Faustman,et al. The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis , 2005, Cellular and Molecular Life Sciences CMLS.
[140] S. Yarkoni,et al. Mechanisms of T regulatory cell function. , 2008, Autoimmunity reviews.
[141] D. Goeddel,et al. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.
[142] L. Tartaglia,et al. The two different receptors for tumor necrosis factor mediate distinct cellular responses. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[143] H. Holtmann,et al. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. , 1990, The Journal of biological chemistry.
[144] D. Faustman,et al. Antigen Processing and Autoimmunity: Evaluation of mRNA Abundance and Function of HLA‐linked Genes a , 1998, Annals of the New York Academy of Sciences.
[145] George Kollias,et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor , 1995, Cell.
[146] L. Klareskog,et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.
[147] M. Lenardo,et al. Induction of apoptosis in mature T cells by tumour necrosis factor , 1995, Nature.
[148] V. D’Agati,et al. Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis , 2005 .
[149] Schumacher Hr,et al. Leukocytoclastic vasculitis due to etanercept. , 2000 .
[150] T. Laessig,et al. Suppression of Death Receptor Signaling in Cerebellar Purkinje Neurons Protects Neighboring Granule Neurons from Apoptosis via an Insulin-like Growth Factor I-dependent Mechanism* , 2002, The Journal of Biological Chemistry.
[151] J. Stroehlein,et al. Pustular psoriasis induced by infliximab. , 2004, Journal of drugs in dermatology : JDD.
[152] J. Guilhou,et al. Psoriatic lesions induced by antitumour necrosis factor‐α treatment: two cases , 2004, The British journal of dermatology.